Sfoglia per AUTORE
MASI G
Collezione AO Cuneo

  

Items : 19

Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. in Cancers / Cancers (Basel). 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900.

2023
ASL Biella
AO Cuneo

Masi G; Aprile G; Fornaro L; De Manzoni G; Basile D; Bencivenga M; Vasile E; Leone F; Montagnani F; Puzzoni M; Scartozzi M; Ribero D; Vivaldi C; Fanotto V; Salani F;

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. in British journal of cancer / Br J Cancer. 2021 Jan;124(1):183-190. doi: 10.1038/s41416-020-01089-9. Epub 2020 Oct 7.

2021
AO Cuneo
AOU Città della Salute di Torino

Falcone A; Cremolini C; Rapisardi S; Masi G; Latiano TP; Moretto R; Pietrantonio F; Ritorto G; Buonadonna A; Zaniboni A; Caponnetto S; Ricci V; Bergamo F; Ermacora P; Germani MM; Antoniotti C; Tomasello G; Santini D; Lonardi S; Rossini D;

Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Aug;153:16-26. doi: 10.1016/j.ejca.2021.04.039. Epub 2021 Jun 12.

2021
AO Cuneo

Falcone A; Masi G; Fontanini G; Ugolini C; Bertolini AS; Germani MM; Clavarezza M; Frassoldati A; Granetto C; Conca V; Lonardi S; Aprile G; Tomasello G; Pietrantonio F; Boccaccino A; Passardi A; Poma AM; Moretto R; Giordano M; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AOU Città della Salute di Torino
AO Cuneo

Fenocchio E; Mammoliti S; Cupini S; Roselli M; Mambrini A; Ritorto G; Clavarezza M; Carlomagno C; Di Donato S; Ronzoni M; Masi G; Tomasello G; Antonuzzo L; Corallo S; Cordio S; Moretto R; Buonadonna A; Granetto C; Murgioni S; Zaniboni A; Aprile G; Grande R; Marmorino F; Passardi A; Santini D; Tamburini E; Latiano TP; Bordonaro R; Pietrantonio F; et alii...

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

2019
AO Cuneo

Fontanini G; Lonardi S; Sensi E; Tonini G; Schirripa M; Granetto C; Delfanti S; Di Donato S; Casagrande M; Gemma D; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Masi G; Salvatore L; Aprile G; Bergamo F; Marmorino F; Cremolini C; Boni L; Falcone A;

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C;

Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib in Annals of Oncology

2019
AO Cuneo
AOU Città della Salute di Torino

Ricci V; Falletta A; Granetto C; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano M; Zucchelli G; Marmorino F; Rossini D; Aprile G; Casagrande M; Lonardi S; Murgioni S; Dell'Aquila E; Tomasello G; Moretto R; Antoniotti C; Borelli B; Urbano F; Ronzoni M; Zaniboni A; Manglaviti S; Buonadonna A; Ritorto G; Masi G; Allegrini G; et alii...

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC in Journal of Clinical Oncology

2019
AO Cuneo

Cremolini C; Antoniotti C; Lonardi S; Rossini D; Pietrantonio F; Cordio SS; Bergamo F; Marmorino F; Maiello E; Passardi A; Masi G; Tamburini E; Santini D; Grande R; Zaniboni A; Granetto C; Murgioni S; Aprile G; Boni L; Falcone A;

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

2018
AO Cuneo
AOU Città della Salute di Torino

Zagonel V; Sensi E; Masi G; Granetto C; Allegrini G; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Racca P; Ronzoni M; Moretto R; Tomasello G; Bergamo F; Cortesi E; Lonardi S; Antoniotti C; Cremolini C; Fontanini G; Boni L; Falcone A;

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.

2018
AO Cuneo
AOU Città della Salute di Torino

Santini D; Boni L; Falcone A; Tomcikova D; Tonini G; Chiara S; Di Donato S; Allegrini G; Fea E; Buonadonna A; Racca P; Tomasello G; Zaniboni A; Ronzoni M; Urbano F; Schirripa M; Marmorino F; Stellato M; Masi G; Lonardi S; Bergamo F; Zeppola T; Cremolini C; Dell'Aquila E;

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Falcone A; Boni L; Cremolini C; Delliponti L; Vitello S; Antonuzzo L; Martinelli E; Vannini F; Marsico VA; Colombo C; Granetto C; Leone F; Passardi A; Boccaccino A; Pella N; Di Battista M; Martignetti A; Zaniboni A; Zucchelli G; Salvatore L; Rossini D; Marmorino F; Burgio V; Masi G; Pietrantonio F; Bonetti A; Antoniotti C; Lonardi S; Borelli B; et alii...

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

2017
AO Cuneo

Pellegrinelli A; Sensi E; Pilati P; Cillo U; Urbani L; Granetto C; Ferrari L; Allegrini G; Tonini G; Tomasello G; Zucchelli G; Marmorino F; Pietrantonio F; Moretto R R; Masi G; Bergamo F; Aprile G; Loupakis F; Cremolini C; Casagrande M; Milione M; Fontanini G; Falcone A;

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. in BMC cancer / BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

2017
AO Cuneo

Santini D; Allegrini G; Di Donato S; Passardi A; Tomasello G; Valsuani C; Pietrantonio F; Ronzoni M; Ricci V; Tamburini E; Aprile G; Lonardi S; Zagonel V; Boni L; Schirripa M; Salvatore L; Antoniotti C; Masi G; Loupakis F; Marmorino F; Cremolini C; Falcone A;

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A;

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies in Journal of Clinical Oncology

2016
AO Cuneo

Casagrande M; Moretto R; Loupakis F; Cremolini C; Masi G; Borelli B; Lonardi S; Marsico VA; Ferrari L; Ricci V; Grande R; Tomasello G; Ronzoni M; Allegrini G; Tonini G; Mancini ML; Zaniboni A; Chiara S; Carlomagno C; Falcone A;

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

2015
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Loupakis F; Antoniotti C; Lonardi S; Masi G; Salvatore L; Cortesi E; Tomasello G; Spadi R; Zaniboni A; Tonini G; Barone C; Vitello S; Longarini R; Bonetti A; D'Amico M; Di Donato S; Granetto C; Boni L; Falcone A;

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

2015
AO Cuneo

Falcone A; Amoroso D; Bonetti A; Chiara S; Allegrini G; Boni C; Fea E; Antonuzzo L; Granetto C; Barbara C; Safina V; Cupini S; Schirripa M; Cremolini C; Fornaro L; Boni L; Masi G; Loupakis F; Salvatore L;

Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO) in Journal of Clinical Oncology

2013
AO Cuneo

Masi G; Loupakis F; Salvatore L; Cremolini C; Fornaro L; Schirripa M; Granetto C; Miraglio E; Di Costanzo F; Antonuzzo L; Marcucci L; Barbara C; Boni C; Banzi M; Chiara S; Garbarino D; Valsuani C; Bonetti A; Boni L; Falcone A;